Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 1.89% 13.50 13.00 14.00 13.625 13.25 13.25 477,916 10:02:51
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -7.2 -4.5 - 33

Futura Medical Share Discussion Threads

Showing 16751 to 16769 of 18775 messages
Chat Pages: Latest  679  678  677  676  675  674  673  672  671  670  669  668  Older
DateSubjectAuthorDiscuss
03/5/2019
10:42
What is interesting is that thus far there has been no RNS relating to a change in share holdings,in particular Lombard's holding.I hope that I am not speaking to soon,but this must be a positive.
martinelwick
03/5/2019
09:03
Definitely one to hold long term
akmal101
03/5/2019
06:46
The global topical pain relief market is much bigger than the ED market and with rapidly ageing populations, is set for continued strong growth. FUM have another potential huge winner in this sector. Eye watering potential when you combine the ED and Pain relief market sizes. Not long now.
j777j
02/5/2019
15:47
From Futura website re TPR100: "A marketing authorisation filing was submitted by Thornton and Ross in July 2018 and await responses and action from the UK regulator."
rrr
02/5/2019
15:45
Not new, just a reminder: hTTp://www.thorntonandross.co.uk/newsPage.aspx?from=Futura "Thornton & Ross Ltd sign licensing agreement for novel pain relief gel Thornton & Ross (T&R) are pleased to announce they have entered in to a long-term licensing agreement with Futura Medical, specialists in transdermal drug technology, for their novel topical diclofenac gel, TPR100. Under the terms of the agreement, Thornton & Ross will conduct the manufacturing scale-up of TPR100 and hold rights to manufacture, market and distribute the product in the UK for the lifetime of the product's patents, which run to at least 2028 in the UK. TPR100, which benefits from the rapid skin permeation rates offered by Futura's proprietary DermaSys® delivery system, demonstrated statistically significant results in a 2015 clinical study comparing the product against both placebo and currently marketed products. Dieno George, Executive Vice President of Brands at STADA, said: "Thornton & Ross is an ideal partner for Futura, with its expertise in both OTC and Rx marketing and we are very excited to bring TPR100 into our product portfolio. TPR100's topical formulation, and positive trial results achieved to date, mean that it has the potential to be a product that very successfully meets patient needs." Barry Draude, Managing Director at T&R, said: "Thornton & Ross are always seeking innovative technology that brings real benefits to patients and consumers and Futura's TPR100 is an excellent example of this. Futura are experts in topical pain relief and we look forward to working with them and to bringing this exciting product to market""
rrr
02/5/2019
11:31
More interested in when the US funds start buying.May have started,good volumes, time will tell.
j777j
02/5/2019
11:20
When do Lombard odier turn up ?
wantage
02/5/2019
06:51
Oh no don't worry about me,I am feeling great and full of energy.
j777j
01/5/2019
18:47
J777J, you must be worn out, have you thought of taking a break?
glavey
01/5/2019
16:56
& volumes are well up 1
mikethebike4
01/5/2019
10:00
"Clearly, the shares are not for the faint-hearted, but if you can stomach the risk then Futura's share price has the potential to multiply many times over if the £30m market capitalisation company delivers the headline data that potential commercial partners are looking for. So, having taken into account the latest update from the directors, I continue to rate the shares a buy."Investors chronicle."Has the potential to multiply many times over"Say what?Obviously invest with eyes open but these don't come around that often."Potential to multiply many times over."Say what??????Obviously invest with eyes open but...
j777j
01/5/2019
09:15
this is more like it !
mikethebike4
01/5/2019
08:42
So cheap it's crazy.Imho
j777j
29/4/2019
11:43
Do people ever question why the poor remain poor and the rich get richer?
j777j
29/4/2019
09:28
Sorry I should have explained the 15%,is the level of royalties for the Med gel,forecast by Singer the house broker presumably with the closest ear to the company.
j777j
29/4/2019
09:05
What is 15% of $1.4 billion (estimated peak sales of Med2005?)What is current market cap?Do the maths and realise this is a pretty rare risk reward opportunity.Singer expects a further $90 million in upfront and milestone payment for Europe and the USA. Compare all that to the Current market cap of £36 million and 170p is potentially only base camp.GLAYou only live once.
j777j
24/4/2019
14:17
Re "I see this heading well over 170p".....I soooooooooooooo wish that was more than mere wishful thinking.
freddievas
24/4/2019
07:24
Marvellous.
j777j
19/4/2019
01:03
Anyway, lovely weather isnt it?
andyj
Chat Pages: Latest  679  678  677  676  675  674  673  672  671  670  669  668  Older
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200221 16:29:25